Literature DB >> 30767097

Predictive factors for acute thrombogenesis occurring immediately after bypass procedure for moyamoya disease.

Takeshi Mikami1, Hime Suzuki2, Ryo Ukai2, Katsuya Komatsu2, Yukinori Akiyama2, Masahiko Wanibuchi2, Kiyohiro Houkin3, Nobuhiro Mikuni2.   

Abstract

Extracranial-to-intracranial (EC-IC) bypass surgery is an effective treatment for patients with moyamoya disease and other conditions. Some patients with moyamoya disease have a risk of acute thrombogenesis at the anastomotic site just after bypass surgery. The purpose of this study was to study risk factors of acute thrombogenesis and determine effective countermeasures. This study included 48 patients (66 EC-IC bypass procedures) with moyamoya disease and 52 controls (54 procedures) without moyamoya disease. The development of acute thrombogenesis was compared between the moyamoya disease and control groups. In the moyamoya disease group, clinical and radiological characteristics were assessed with respect to acute thrombogenesis. In the patients with acute thrombogenesis, causes of technical problems were retrospectively examined. The incidence of acute thrombogenesis was significantly higher in the moyamoya disease group than those in the control group. In the moyamoya disease group, acute thrombogenesis was observed in seven patients. In the moyamoya disease group, the magnetic resonance angiography (MRA) scores were significantly higher in patients with acute thrombogenesis than those in the patients without acute thrombogenesis. In the multivariate analysis, the predictive factor of acute thrombogenesis in moyamoya disease was a high MRA score (odds ratio, 2.336; p = 0.009). During EC-IC bypass surgery for moyamoya disease, acute thrombogenesis should be considered to obtain a high patency rate, particularly in patients with high MRA scores. Acute thrombogenesis will not influence morbidity if proper countermeasures are followed; therefore, the prediction and recognition of white thrombus are important for a successful bypass surgery.

Entities:  

Keywords:  Bypass; Complication; Moyamoya disease; Thrombogenesis

Year:  2019        PMID: 30767097     DOI: 10.1007/s10143-019-01086-4

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  32 in total

1.  Venous and arterial thrombosis: a continuous spectrum of the same disease?

Authors:  Carlos Jerjes-Sanchez
Journal:  Eur Heart J       Date:  2004-11-30       Impact factor: 29.983

Review 2.  Moyamoya disease: current concepts and future perspectives.

Authors:  Satoshi Kuroda; Kiyohiro Houkin
Journal:  Lancet Neurol       Date:  2008-11       Impact factor: 44.182

Review 3.  Mechanisms of thrombus formation.

Authors:  Bruce Furie; Barbara C Furie
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

Review 4.  Platelet-based coagulation: different populations, different functions.

Authors:  J W M Heemskerk; N J A Mattheij; J M E M Cosemans
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

5.  Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis).

Authors: 
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

6.  Effect of Aspirin in Postoperative Management of Adult Ischemic Moyamoya Disease.

Authors:  Yahui Zhao; Qian Zhang; Dong Zhang; Yuanli Zhao
Journal:  World Neurosurg       Date:  2017-06-15       Impact factor: 2.104

7.  Characteristics of cerebral hemodynamics assessed by CT perfusion in moyamoya disease.

Authors:  Ayaka Sasagawa; Takeshi Mikami; Toru Hirano; Yukinori Akiyama; Nobuhiro Mikuni
Journal:  J Clin Neurosci       Date:  2017-10-19       Impact factor: 1.961

8.  Pediatric moyamoya disease: An analysis of 410 consecutive cases.

Authors:  Seung-Ki Kim; Byung-Kyu Cho; Ji Hoon Phi; Ji Yeoun Lee; Jong Hee Chae; Ki Joong Kim; Yong-Seung Hwang; In-One Kim; Dong Soo Lee; Joongyub Lee; Kyu-Chang Wang
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

9.  Risk factors for and outcomes of postoperative complications in adult patients with moyamoya disease.

Authors:  Meng Zhao; Xiaofeng Deng; Dong Zhang; Shuo Wang; Yan Zhang; Rong Wang; Jizong Zhao
Journal:  J Neurosurg       Date:  2018-03-01       Impact factor: 5.115

10.  Age-dependent revascularization patterns in the treatment of moyamoya disease in a European patient population.

Authors:  Marcus Czabanka; Peter Vajkoczy; Peter Schmiedek; Peter Horn
Journal:  Neurosurg Focus       Date:  2009-04       Impact factor: 4.047

View more
  5 in total

1.  Non-contrast hemodynamic imaging of Moyamoya disease with MR fingerprinting ASL: A feasibility study.

Authors:  Pan Su; Peiying Liu; Marco C Pinho; Binu P Thomas; Ye Qiao; Judy Huang; Babu G Welch; Hanzhang Lu
Journal:  Magn Reson Imaging       Date:  2022-02-18       Impact factor: 2.546

2.  Delayed reopening of a superficial temporal artery to middle cerebral artery bypass graft occluded by a white thrombus during surgery.

Authors:  Satoshi Takahashi; Kazunari Yoshida
Journal:  Surg Neurol Int       Date:  2020-08-01

3.  Safety, Feasibility, and Patient-Rated Outcome of Sonolucent Cranioplasty in Extracranial-Intracranial Bypass Surgery to Allow for Transcranioplasty Ultrasound Assessment.

Authors:  Alex R Flores; Visish M Srinivasan; Jill Seeley; Charity Huggins; Peter Kan; Jan-Karl Burkhardt
Journal:  World Neurosurg       Date:  2020-08-20       Impact factor: 2.104

4.  <Editors' Choice> Indocyanine green emission timing of the recipient artery in revascularization surgery for moyamoya disease.

Authors:  Fumiaki Kanamori; Yoshio Araki; Kinya Yokoyama; Kenji Uda; Takashi Mamiya; Masahiro Nishihori; Takashi Izumi; Sho Okamoto; Atsushi Natsume
Journal:  Nagoya J Med Sci       Date:  2021-08       Impact factor: 1.131

Review 5.  Implementation and Rationale for a Unified Clinical and Imaging Protocol for Evaluation and Treatment of Moyamoya Angiopathy: A Single Institutional Experience.

Authors:  Anthony S Larson; Vance T Lehman; Luis E Savastano; Giuseppe Lanzino; Norbert G Campeau; Kirk M Welker; James P Klaas
Journal:  Front Neurol       Date:  2021-05-17       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.